A recently launched VA study of mortality in Vietnam veterans will examine whether exposure to liver flukes, a parasitic worm, increased the risk of cholangiocarcinoma or bile duct cancer in those veterans.
Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer/T-cell neoplasms in the United States.
Prevention of AIDS-defining cancers, such as non-Hodgkin lymphoma, can be helped by early, sustained antiretroviral therapy, which results in long-term viral suppression, a new study found.
About a third of hematologic cancer patients in a recent cohort study screened positive for executive dysfunction, and more than 17% had memory problems.
Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).
Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.
In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.
In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).
In March, then-VA Secretary David Shulkin, MD, announced at the annual Wharton Health Care Business Conference that the VA will have eliminated hepatitis C infections among all patients willing and able to be treated by next spring.
While many other cancers have seen dramatic improvement in outcomes in the past 20 years, pancreatic cancer remains one of the deadliest malignancies, regardless of stage at diagnosis, with an overall five-year survival rate of only 8%, according to the American Cancer Society.
Colonoscopy is heavily promoted in the VA healthcare system, and a new study sought to document its effect on colorectal cancer (CRC) mortality rates.
The standard of care for locoregionally advanced rectal cancer (LARC) in the United States usually involves adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME).
While suspected, the relationship between dietary and lifestyle risk factors and long-term mortality from colorectal cancer remains poorly understood, according to a new study.
CTCL 6-10 Times More Common in Veterans; Agent Orange a Factor New Therapies Raise Optimism about Treatment
Chances are, if you haven’t trained or practiced at the VA, you haven’t seen cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin lymphoma.
While the availability of novel therapies is making the future brighter for non-Hodgkin’s lymphoma (NHL) patients, new treatments also are coming on line for Hodgkin’s lymphoma, which is a hematological cancer distinct from NHL.
Because several studies have suggested it fails to increase overall survival (OS) despite prolonging progression-free survival (PFS), use of maintenance rituximab (MR) following chemoimmunotherapy in follicular lymphoma (FL) remains controversial.
Multiple organizations have recommended timely treatment for patients with lung cancer.
The treatment armamentarium for renal cell carcinoma and other genitourinary cancers continues to expand.